Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Alzheimer’s Research UK calls on party leaders to tackle dementia pressures

One in three people living with dementia in England never receive a formal diagnosis

- PMLiVE

MHRA grants two new marketing authorisations for UCB’s inflammatory disease drug

Bimzelx is now approved to treat psoriatic arthritis and axial spondyloarthritis

- PMLiVE

New blood test could one day be used to diagnose Parkinson’s disease

The discovery could potentially lead to the development of a definitive diagnostic test

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

New Outcomes Are a Breath of Fresh Air at ERS

ERS 2023 will mark the new release of outcomes data by Medscape Education Global. During the poster hall sessions on September 12, the Medscape team will present a poster that...

Medscape Education

Top 10 Most Important Advisor Questions: Key Brand Attributes

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's the first one to keep...

Impetus Digital

- PMLiVE

Novo Nordisk acquires Embark Biotech in deal worth over €470m

Novo gains access to Embark's lead asset targeting obesity and other cardiometabolic diseases

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

Biomarin

BioMarin announces first patient dosed with haemophilia A gene therapy in Europe

The therapy was granted conditional marketing authorisation by the EC in August 2022

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

- PMLiVE

eCTD 4.0 is changing the regulatory landscape – what you need to know

All regions that have published guidelines will mandate implementation of eCTD version 4.0 by 2028, with more regions to follow in the future

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links